Gupta et al. (2024)
Food Nutr Res 2024;68:10667
In the treatment group, fasting and postprandial glucose fell by 38% and 44% and HbA1c by about 34.7%; C-peptide, TSH, liver, kidney and cardiovascular markers stayed normal and no adverse events were reported.
- RCT, double-blind
- n=81
- >45% furostanolic saponins
- 1,000 mg/day
- 12 weeks
Full summary
A randomized, double-blind, placebo-controlled trial in adults with type 2 diabetes already taking metformin or metformin with a sulfonylurea (42 analyzed on treatment, 39 on placebo) tested Fenfuro® fenugreek seed extract containing >45% furostanolic saponins by HPLC at 1,000 mg/day (500 mg × 2) for 12 weeks. In the treatment group, fasting and postprandial glucose fell by 38% and 44% and HbA1c by about 34.7%; C-peptide, TSH, liver, kidney and cardiovascular markers stayed normal and no adverse events were reported.


